Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / A Methylation Panel for Bladder Cancer

A Methylation Panel for Bladder Cancer


Participate in a prevalidation study for methylation based detection of bladder cancer. In addition, a panel of three markers identified will be evaluated for their ability to a) identify bladder cancer patients from those with benign urologic disease; b) identify patients with superficial (papillary) cancers from those with high grade invasive cancers

1) Participate in a prevalidation study for methylation based detection of bladder cancer. 2) Collect voided urine specimens from patients with a) invasive carcinomas, b) non-invasive carcinomas, and c) patients with urologic diseases who are free of cancer, including patients with hematuria 3) Test the panel of three methylation markers described in the Preliminary DAta for their ability to identify individuals with bladder cancer and to differentiate between invasive and non-invasive cancers

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

Announcement 6/2/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.